多器官功能障碍综合征相关肾损伤 中国就医指南

Kidney Injury Associated with Multiple Organ Dysfunction Syndrome (KI-MODS) is a life-threatening clinical condition characterized by acute kidney injury (AKI) occurring in the context of systemic organ failure—commonly involving the lungs, liver, cardiovascular system, and hematologic system. It is not a primary renal disease but rather a critical complication of severe sepsis, major trauma, massive transfusion, cardiogenic shock, or post-cardiac surgery states. Pathogenesis centers on dysregulated host inflammatory response, endothelial dysfunction, microcirculatory failure, mitochondrial bioenergetic collapse, and tubular epithelial cell apoptosis or necrosis. Key mediators include cytokines (e.g., IL-6, TNF-α), reactive oxygen species, complement activation, and coagulopathy-induced renal microthrombi. Renal hypoperfusion—both macro- and microvascular—is central, compounded by nephrotoxic exposures (e.g., contrast agents, antibiotics, vasopressors) and metabolic derangements such as hyperbilirubinemia or rhabdomyolysis. Epidemiologically, KI-MODS affects approximately 30–50% of ICU patients with MODS; incidence rises to >60% in septic shock cohorts. Mortality exceeds 50–70% when ≥3 non-renal organs fail alongside AKI, making it one of the highest-mortality phenotypes in critical care nephrology. Risk factors include advanced age (>65 years), pre-existing chronic kidney disease (CKD), diabetes mellitus, hypertension, heart failure, cirrhosis, immunosuppression, and prolonged mechanical ventilation. Patients often present with oliguria or anuria, rising serum creatinine and blood urea nitrogen (BUN), electrolyte imbalances (hyperkalemia, acidosis), fluid overload, and signs of uremia—including confusion, nausea, and pericardial friction rub. Beyond physiological deterioration, KI-MODS profoundly impairs quality of life: survivors frequently experience persistent renal dysfunction (requiring long-term dialysis in 10–20%), cognitive deficits, physical deconditioning, depression, and reduced return-to-work rates. Health-related quality of life scores (e.g., SF-36) show marked declines in physical functioning, vitality, and social role domains, with effects lasting ≥12 months post-ICU discharge. Early recognition via KDIGO AKI criteria (rise in creatinine ≥0.3 mg/dL within 48h or ≥1.5× baseline within 7 days, or urine output <0.5 mL/kg/h for 6h) combined with biomarkers (e.g., TIMP-2•IGFBP7, NGAL) enables timely intervention. Multidisciplinary management—integrating nephrology, critical care, infectious disease, and nutrition support—is essential to mitigate progression and optimize outcomes.

# 多器官功能障碍综合征相关肾损伤治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用于MODS早期（SOFA评分≤8）、血流动力学相对稳定、AKI KDIGO 1–2期患者。

• •基础支持：连续性肾脏替代治疗（CRRT）+血管活性药物+液体管理，日均费用 3,800–6,500元（含滤器、置换液、抗凝药）；
• •药物干预：去甲肾上腺素泵入、呋塞米静脉滴注、碳酸氢钠纠酸等，日均药费 420–980元；
• •检验监测：每日血气分析、电解质、肌酐、乳酸、炎症指标（PCT/IL-6），单次检查费 320–560元。

二、介入/核心支持方案

适用于MODS进展期（SOFA≥9）、AKI 3期伴容量过负荷或严重电解质紊乱者。

• •CRRT升级为CVVHDF联合内毒素吸附（如PMX-DHP）：单次治疗费 8,200–12,600元（含吸附柱、专用管路）；
• •术前检查（心超、下腔静脉超声、凝血四项+TEG、床旁胸片）：合计 1,450–2,100元。

三、特殊复杂方案

晚期合并脓毒症休克、难治性高钾血症或CRRT依赖＞72h者：

• •多模式血液净化（CRRT+HP+PE）联合免疫调节（托珠单抗）：单周期（3天）总费用 28,000–45,000元。

方案快速选择指南

• •预算有限/轻中度AKI：首选标准CRRT+药物支持（日均约4,500元）；
• •重症MODS/需精准清除介质：选CVVHDF+PMX-DHP（首日投入约1.1万元）；
• •顽固性器官衰竭：启动多模式净化+靶向免疫干预（单周期预算≥3万元）。